NCT03442088View on ClinicalTrials.gov

Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Plaque Psoriasis
Interventions
DRUG

Apremilast

Apremilast will be given as approved by the FDA for the treatment of moderate to severe plaque psoriasis. An initial dosage titration from Day 1 (10mg) to Day 5 (30mg). Following the titration, the recommended maintenance dosage of 30 mg twice daily taken orally starting on Day 6 will be dispensed, as per labeled indication.

Trial Locations (1)

44106

University Hospitals Cleveland Medical Center, Cleveland

All Listed Sponsors
lead

University Hospitals Cleveland Medical Center

OTHER

NCT03442088 - Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast | Biotech Hunter | Biotech Hunter